This top fund manager just called these leading ASX shares a buy

WAM thinks that these two ASX shares are buys.

| More on:
A stopwatch ticking close to the 12 where the words on the face say 'Time to Buy' indicating its the bottom of the falling market and time to buy ASX shares

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Fund manager Wilson Asset Management (WAM) has outlined two ASX shares with potential
  • The first stock is pathology business Australian Clinical Labs which is benefiting from the high level of COVID testing
  • The second company is building and restoration services Johns Lyng which is growing market share and opening up new growth opportunities

Leading fund manager Wilson Asset Management (WAM) has named two ASX shares in its portfolios that it thinks are buys.

Every month, WAM talks about some of the businesses that have performed well and outlines the bullish factors for thinking about the stocks.

Two of the featured ASX shares this month comes from WAM Research Limited (ASX: WAX) and WAM Capital Limited (ASX: WAM), which sometimes target opportunities from the smaller end of the ASX, like these two:

Australian Clinical Labs Ltd (ASX: ACL)

Australian Clinical Labs is described as a leading provider of pathology services in Australia, with 86 accredited laboratories performing services for more than 8 million people annually.

In December, Australian Clinical Labs upgraded its expectations for the FY22 first-half net profit after tax (NPAT) to between $116.3 million to $128 million. This was increased from the previous guidance of between $86.3 million to $94.9 million.

The fund manager notes that the ASX share is experiencing strong demand for coronavirus testing, particularly during the Omicron variant outbreak and recently completed the acquisition of Medlab Pathology, doubling its market share to 20.4% in New South Wales.

WAM thinks that Australian Clinical Labs is a high-quality pathology business that can continue to grow organically through market share gains, due to its "superior technology and processes". The fund manager notes that Australian Clinical Labs has a very strong balance sheet and it also sees the potential for acquisitions in the future that can add to profit.

Johns Lyng Group Ltd (ASX: JLG)

Another ASX share that WAM likes is Johns Lyng which provides building and restoration services across Australia for properties and contents damaged by insurable events, including impact, weather, and fire events.

It operates in all major metropolitan areas and in high-risk regional areas, such as Far North Queensland.

WAM pointed out that in December, the company announced the acceleration of its US growth strategy through the acquisition of Reconstruction Experts, a leading provider of insurance-focused vendor managed repairs services for US$144 million.

This acquisition, considered highly strategic, adds to the company's earnings per share (EPS) and equated to 7.8x earnings before interest, tax, depreciation and amortisation (EBITDA) for the 12 months to 30 June 2021.

The fund manager decided to invest in Johns Lyng Group based on the view that as the largest and most sophisticated provider of emergency building works, the company will continue to grow through market share gains and acquisition.

WAM believes that with the recent acquisition, the company has added another material growth pillar that will underpin longer-term aspirations and earnings growth.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Australian Clinical Labs Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Opinions

A man casually dressed looks to the side in a pensive, thoughtful manner with one hand under his chin, holding a mobile phone in his hand while thinking about something.
Opinions

Where I'd invest $10,000 in 2026 in ASX shares aiming to beat the market

These businesses look like very appealing buys today.

Read more »

a woman with lots of shopping bags looks upwards towards the sky as if she is pondering something.
Opinions

The pros and cons of buying Zip shares in 2026

There are positive and negative aspects about Zip shares right now…

Read more »

Two people lazing in deck chairs on a beautiful sandy beach throw their hands up in the air.
Dividend Investing

A dividend giant I'd buy over BHP shares right now!

This stock is much more appealing to me than BHP. Here’s why…

Read more »

Super profit tax ASX miners one hundred dollar notes floating around representing asx share price growth
Dividend Investing

I'd buy 21,819 shares of this ASX stock to aim for $200 a month of passive income

This business is an impressive option for significant dividend cash flow.

Read more »

A stressed businessman in a suit shirt and trousers sits next to his briefcase with his head in his hands while the ASX boards behind him show BNPL shares crashing
Opinions

2 buys and 1 sell for investors worried about an ASX market crash in 2026

Here's how to prepare.

Read more »

A handful of Australian $100 notes, indicating a cash position
Dividend Investing

1 ASX dividend stock down 36% I'd buy right now

This stock may be trading far too cheap.

Read more »

a pot of gold at the end of a rainbow
Opinions

Why this could be the easiest way to become a millionaire with shares on the ASX

This investment could offer everything an investor is looking for.

Read more »

Rising green bar graph with an arrow and a world map, symbolising a rising share price.
Opinions

2 ASX shares to buy and hold for the next decade!

These two businesses have a very exciting outlook.

Read more »